Timm Medical Technologies, Inc and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Published: Oct 14, 2009
MINNEAPOLIS, Oct. 14 /PRNewswire/ -- Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.
Under the agreement, Timm Medical will be responsible for promoting Prosed(R) DS to urologists and retail pharmacists in the United States. Ferring will continue to promote Prosed(R) DS to physicians in the United States and will retain responsibility for manufacturing, supply and regulatory affairs. Financial terms of the agreement were not disclosed.
Prosed(R) DS is a urinary analgesic, antiseptic and antispasmodic combination. Prosed(R) DS has a long history of use for the treatment of pain and discomfort of the lower urinary tract.
"We are excited to partner with Ferring Pharmaceuticals to promote this well-established treatment for urinary discomfort," commented David Talen, President of Timm Medical. "Timm Medical and Ferring Pharmaceuticals share a commitment to urologists and the care of their patients. Timm Medical's flagship product, the Osbon ErecAid, has a 30-year history of providing safe, effective and reliable treatment for men suffering from erectile dysfunction. Prosed(R) DS has the same outstanding reputation as an effective treatment for the pain associated with urological procedures, inflammatory diseases and infections, and represents a natural complement to our product portfolio."
About Timm Medical
Timm Medical is a specialist urology company owned by affiliates of Paul Capital Healthcare. Timm Medical offers products in the areas of erectile function and incontinence. Through its sales force in the United States, Timm calls on over 3,000 urology practices. In addition, Timm distributes products via a 60+ international distributor network. For more information, contact David Talen, President or visit www.timmmedical.com.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, FIRMAGON(R) (degarelix for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA(R) (1% sodium hyaluronate).
Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
SOURCE Timm Medical Technologies, Inc.
CONTACT: David Talen, President of Timm Medical, 1-800-683-8938; or
Ferring Pharmaceuticals, 1-888-FERRING (1-888-337-7464)
Web site: http://www.timmmedical.com/